Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, AbCellera Biologics Inc. reported revenue of $75M, up 160.6% year over year. Operating margin was -289.0% and net margin -194.9%, on a free-cash-flow margin of -231.7% with capital expenditure at 56.9% of revenue. Every figure is computed directly from ABCL's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $75M | -289.0% | -194.9% |
| FY2024 | $29M | -1091.7% | -564.8% |
| FY2023 | $38M | -623.8% | -385.0% |
| FY2022 | $485M | 44.6% | 32.7% |
| FY2021 | $375M | 54.5% | 40.9% |
How does ABCL compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 23 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: PG · JNJ · ABBV · BMY · ABT · AMGN
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.